Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | ACHE | P22303 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.54 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.54 |
| ▸ | EBP | Q15125 | 2/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.53 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.53 |
| ▸ | DRD2 | P14416 | 1/20 | 0.53 |
| ▸ | DRD3 | P35462 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7315240 | 0.89 | SIGMAR1 (0.57) | HSP90AA1ALDH1A1ACHEMAPK1EBP | |
| SCHEMBL4281747 | 0.82 | HSP90AA1 (0.56) | HSP90AA1ALDH1A1HTTSMN1; SMN2ACHE | |
| SCHEMBL13988594 | 0.81 | HSP90AA1 (0.55) | HSP90AA1ALDH1A1HTTSMN1; SMN2ACHE | |
| SCHEMBL9028169 | 0.79 | SIGMAR1 (0.61) | HSP90AA1ALDH1A1HTTSMN1; SMN2LMNA | |
| SCHEMBL10195155 | 0.79 | HSP90AA1 (0.67) | HSP90AA1ALDH1A1HTTSMN1; SMN2LMNA | |
| SCHEMBL12821148 | 0.77 | POLB (0.59) | HSP90AA1ALDH1A1HTTSMN1; SMN2ACHE | |
| SCHEMBL14678150 | 0.76 | HSP90AA1 (1.00) | HSP90AA1ALDH1A1HTTSMN1; SMN2LMNA | |
| SCHEMBL16641094 | 0.75 | CYP19A1 (0.77) | HSP90AA1ALDH1A1KDM4EMAPT | |
| SCHEMBL31157848 | 0.75 | CYP19A1 (0.77) | HSP90AA1ALDH1A1KDM4EMAPT | |
| SCHEMBL27337543 | 0.75 | SIGMAR1 (0.64) | HSP90AA1EBPSIGMAR1TMEM97 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6403805-B1 | SUCH AS 1-((1-(3-(CYCLOPENTYLOXY)-4-METHOXYPHENYL) CYCLOPROPYL)METHYL)-1,3-DIHYDRO-2H-IMIDAZOL-2-ONE FOR ALLERGIES, ATOPIC AND INFLAMMATORY DISEASES WHEREIN ACTIVITY OF PHOSPHODIESTERASE IS ALTERED | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-06-11 | — | — | US | claimed |
| US-20020068830-A1 | 1,3-DIHYDRO-1-(PHENYLALKYL)-2H-IMIDAZOL-2-ONE DERIVATIVES | FREYNE EDDY JEAN EDGARD (BE) | 2002-06-06 | — | — | US | claimed |
| EP-0819122-B1 | 1,3-DIHYDRO-1-(PHENYLALKYL)-2H-IMIDAZOL-2-ONE DERIVATIVES HAVING PDEIV AND CYTOKINE ACTIVITY | JANSSEN PHARMACEUTICA NV (BE) | 2002-03-06 | — | — | EP | claimed |
| EP-0819122-A1 | 1,3-DIHYDRO-1-(PHENYLALKYL)-2H-IMIDAZOL-2-ONE DERIVATIVES HAVING PDEIV AND CYTOKINE ACTIVITY | JANSSEN PHARMACEUTICA N.V. (BE) | 1998-01-21 | — | — | EP | claimed |
| WO-1996031485-A1 | 1,3-DIHYDRO-1-(PHENYLALKYL)-2H-IMIDAZOL-2-ONE DERIVATIVES HAVING PDEIV AND CYTOKINE ACTIVITY | JANSSEN PHARMACEUTICA N.V. (BE) | 1996-10-10 | — | — | WO | claimed |
| US-8354434-B2 | Cyclourea compounds as calcium channel blockers | PURDUE PHARMA L.P. (US) | 2013-01-15 | — | — | US | disclosed |
| US-20120322830-A1 | Cyclourea Compounds as Calcium Channel Blockers | PURDUE PHARMA L.P. (US) | 2012-12-20 | — | — | US | disclosed |
| US-20090176838-A1 | Cyclourea Compounds as Calcium Channel Blockers | PURDUE PHARMA L.P. (US) | 2009-07-09 | — | — | US | disclosed |
| EP-1987009-A1 | CYCLOUREA COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | EURO-CELTIQUE S.A. (LU) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007085357-A1 | CYCLOUREA COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | EURO-CELTIQUE S.A. (LU) | 2007-08-02 | — | — | WO | disclosed |
| US-6403805-B1 | SUCH AS 1-((1-(3-(CYCLOPENTYLOXY)-4-METHOXYPHENYL) CYCLOPROPYL)METHYL)-1,3-DIHYDRO-2H-IMIDAZOL-2-ONE FOR ALLERGIES, ATOPIC AND INFLAMMATORY DISEASES WHEREIN ACTIVITY OF PHOSPHODIESTERASE IS ALTERED | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-06-11 | — | — | US | disclosed |
| US-20020068830-A1 | 1,3-DIHYDRO-1-(PHENYLALKYL)-2H-IMIDAZOL-2-ONE DERIVATIVES | FREYNE EDDY JEAN EDGARD (BE) | 2002-06-06 | — | — | US | disclosed |
| EP-0819122-B1 | 1,3-DIHYDRO-1-(PHENYLALKYL)-2H-IMIDAZOL-2-ONE DERIVATIVES HAVING PDEIV AND CYTOKINE ACTIVITY | JANSSEN PHARMACEUTICA NV (BE) | 2002-03-06 | — | — | EP | disclosed |
| US-5994376-A | PHOSPHODIESTERASE INHIBITOR | JANSSEN PHARMACEUTICA, N.V. (BE) | 1999-11-30 | — | — | US | disclosed |
| EP-0819122-A1 | 1,3-DIHYDRO-1-(PHENYLALKYL)-2H-IMIDAZOL-2-ONE DERIVATIVES HAVING PDEIV AND CYTOKINE ACTIVITY | JANSSEN PHARMACEUTICA N.V. (BE) | 1998-01-21 | — | — | EP | disclosed |
| WO-1996031485-A1 | 1,3-DIHYDRO-1-(PHENYLALKYL)-2H-IMIDAZOL-2-ONE DERIVATIVES HAVING PDEIV AND CYTOKINE ACTIVITY | JANSSEN PHARMACEUTICA N.V. (BE) | 1996-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120322830-A1 | Cyclourea Compounds as Calcium Channel Blockers | CACNA1E, CACNA1B, CACNA1D | HSP90AA1 4513/4885ALDH1A1 4063/4885HTT 2479/4885 |
| US-20020068830-A1 | 1,3-DIHYDRO-1-(PHENYLALKYL)-2H-IMIDAZOL-2-ONE DERIVATIVES | HRH2, CBR1, HRH1 | HSP90AA1 1713/4885ALDH1A1 351/4885HTT 3911/4885 |
| US-20090176838-A1 | Cyclourea Compounds as Calcium Channel Blockers | CACNA1E, CACNA1B, CACNA1D | HSP90AA1 4513/4885ALDH1A1 4063/4885HTT 2479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.